Experience relief from symptoms such as dryness and irritation caused by Meibomian Gland Dysfunction. Meibomian Gland Dysfunction is a condition where the glands that help keep your tear film oily get blocked, causing your tears to evaporate more easily and drying your eyes out.
Dry Eye is a chronic disease caused by deficiencies in the quantity and quality of meibum within the tear film that affects over 6 million people in the Canada. As sufferers struggle with symptoms such as dryness and irritation, many try to treat the problem themselves with artificial tears, but may still experience dry eye symptoms.
We know that 86% of dry eye sufferers are reported to have clinical signs of Meibomian Gland Dysfunction (MGD), and now, targeted treatment is here.
To understand how iLux works, you must first understand a bit more about the tears themselves. There are three main components that are crucial in forming the tear film that coats the cornea and keeps your eyes feeling moist and comfortable:
When we experience eye dryness, we generally assume it is due to an Aqueous Layer Deficiency (ALD). An ALD occurs when our eyes do not produce enough of the watery component of tears. However, your dry eye symptoms are likely the sign of something more. 86% of dry eye sufferers have Meibomian Gland Dysfunction (MGD). MGD is a condition where the glands that help keep your tear film oily get blocked:
This allows your tears to evaporate more easily, causing your eyes to dry out. MGD is a chronic condition that will worsen over time if not treated.
The good news is that MGD is manageable.
Fast and Effective
With your eye care professional by your side every step of the way, the iLUX® MGD treatment system administers therapeutic heat and then expresses the oil directly from the blocked meibomian glands. Now that the glands are unblocked, it will be easier for the oil to be released naturally.
Real Dry Eye Relief
The iLUX® device was shown to significantly reduce dry eye symptoms such as gritty eyes and irritation. In a clinical study, patients’ meibomian gland scores were three times better at two weeks post-treatment and four times better at four weeks, compared to baseline.